Insider Selling: United Therapeutics (NASDAQ:UTHR) COO Sells 22,500 Shares of Stock

United Therapeutics Corporation (NASDAQ:UTHR) COO Michael Benkowitz sold 22,500 shares of the stock in a transaction that occurred on Monday, December 15th. The stock was sold at an average price of $496.30, for a total transaction of $11,166,750.00. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink.

Michael Benkowitz also recently made the following trade(s):

• On Monday, December 8th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $478.58, for a total transaction of $10,768,050.00.
• On Monday, December 1st, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $479.91, for a total value of $10,797,975.00.
• On Monday, November 24th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $473.66, for a total value of $10,657,350.00.
• On Monday, November 17th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $470.43, for a total value of $10,584,675.00.
• On Monday, November 10th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $452.07, for a total value of $10,171,575.00.
• On Monday, November 3rd, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The shares were sold at an average price of $429.25, for a total value of $9,658,125.00.
• On Monday, October 27th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $417.50, for a total value of $9,393,750.00.
• On Monday, October 20th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $427.41, for a total transaction of $9,616,725.00.
• On Monday, October 13th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $440.35, for a total transaction of $9,907,875.00.
• On Monday, October 6th, Michael Benkowitz sold 22,500 shares of United Therapeutics stock. The stock was sold at an average price of $450.24, for a total transaction of $10,130,400.00.

United Therapeutics Stock Performance

Shares of NASDAQ:UTHR traded down $0.30 during trading hours on Tuesday, reaching $500.00. The stock had a trading volume of 483,805 shares, compared to its average volume of 578,260. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $502.77. The firm’s 50 day moving average is $458.75 and its 200-day moving average is $376.11. The stock has a market capitalization of $21.53 billion, a price-to-earnings ratio of 18.95, a P/E/G ratio of 4.90 and a beta of 0.86.

United Therapeutics (NASDAQ:UTHR) last issued its earnings results on Wednesday, October 29th. The biotechnology company reported $7.16 EPS for the quarter, topping analysts’ consensus estimates of $6.89 by $0.27. The firm had revenue of $799.50 million during the quarter, compared to the consensus estimate of $812.87 million. United Therapeutics had a net margin of 40.65% and a return on equity of 18.83%. The company’s revenue was up 6.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $6.39 earnings per share. Analysts forecast that United Therapeutics Corporation will post 24.48 EPS for the current year.

Institutional Inflows and Outflows

A number of institutional investors have recently bought and sold shares of the business. CWM LLC boosted its holdings in United Therapeutics by 204.3% during the second quarter. CWM LLC now owns 5,194 shares of the biotechnology company’s stock worth $1,492,000 after buying an additional 3,487 shares in the last quarter. AXQ Capital LP increased its holdings in United Therapeutics by 495.4% in the second quarter. AXQ Capital LP now owns 3,888 shares of the biotechnology company’s stock valued at $1,117,000 after buying an additional 3,235 shares in the last quarter. Wealth Enhancement Advisory Services LLC lifted its position in shares of United Therapeutics by 77.4% during the 2nd quarter. Wealth Enhancement Advisory Services LLC now owns 6,084 shares of the biotechnology company’s stock valued at $1,792,000 after acquiring an additional 2,655 shares during the period. State of Alaska Department of Revenue boosted its stake in shares of United Therapeutics by 17.0% during the 2nd quarter. State of Alaska Department of Revenue now owns 19,532 shares of the biotechnology company’s stock worth $5,612,000 after acquiring an additional 2,840 shares in the last quarter. Finally, Sequoia Financial Advisors LLC boosted its stake in shares of United Therapeutics by 60.0% during the 2nd quarter. Sequoia Financial Advisors LLC now owns 1,067 shares of the biotechnology company’s stock worth $307,000 after acquiring an additional 400 shares in the last quarter. 94.08% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

A number of research analysts have recently commented on the company. UBS Group increased their price objective on United Therapeutics from $580.00 to $600.00 and gave the company a “buy” rating in a report on Thursday, November 6th. Wells Fargo & Company increased their price target on shares of United Therapeutics from $414.00 to $423.00 and gave the company an “equal weight” rating in a research note on Thursday, October 30th. Oppenheimer raised their price objective on shares of United Therapeutics from $510.00 to $575.00 and gave the stock an “outperform” rating in a report on Friday, September 5th. Royal Bank Of Canada upped their target price on shares of United Therapeutics from $569.00 to $587.00 and gave the company an “outperform” rating in a report on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 target price on shares of United Therapeutics in a research report on Wednesday, October 29th. Eight analysts have rated the stock with a Buy rating and three have given a Hold rating to the company’s stock. Based on data from MarketBeat.com, United Therapeutics presently has a consensus rating of “Moderate Buy” and a consensus price target of $505.00.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.